Every quarter I take a look at the top FTSE 100 companies in each of the index’s 10 industries to see how they shape up as a potential starter portfolio.
The table below shows the 10 heavyweights and their valuations based on forecast 12-month price-to-earnings (P/E) ratios and dividend yields.
|Company||Industry||Recent share price (p)||P/E||Yield (%)|
|British American Tobacco (LSE: BATS)||Consumer Goods||4,774||15.5||4.1|
|GlaxoSmithKline (LSE: GSK)||Health Care||1,530||13.6||5.2|
|Rio Tinto||Basic Materials||3,685||12.4||4.8|
|Royal Dutch Shell||Oil & Gas||2,336||16.3||6.2|
Before looking at which individual companies might be particularly good buys today, let’s get a feel for the overall value. The table below shows average P/Es and yields for the group as a whole for the last four quarters and six years.
My rule of thumb is that an average P/E below 10 is bargain territory, 10-14 is good value and above 14 starts to move towards expensive.
As you can see, the P/E has edged up this quarter after three successive falls and remains towards the expensive end of my valuation spectrum. This doesn’t mean that the group of companies can’t deliver a good return for investors, just that it could take longer to achieve than if the stocks were bought at a lower valuation.
Sin stock on offer
British American Tobacco (BAT) is one stock I’d highlight as looking particularly buyable today. The current P/E of 15.5 is a little above my 10-14 good value segment but so-called ‘defensive’ sectors, such as tobacco, routinely trade on higher P/Es.
BAT’s P/E was 17.6 last quarter and I have to go back to my October 2014 review to find the last time it was available on a P/E as low as the current 15.5. The current dividend yield of 4.1% also compares favourably with last quarter’s 3.7%.
At 4,774p, BAT’s shares are down 8.8% from 5,234p last quarter, despite a modest upgrade to its forward 12-month earnings and dividend forecasts. This combination of factors has led to today’s significantly lower P/E and more generous yield.
Health choice also cheap
GlaxoSmithKline (GSK) is another defensive stock I’d highlight as looking very buyable today. I have to go back to my January 2014 review to find the last time this stock was available on a P/E as low as its current 13.6. And it was three quarters ago that it was last offering a yield as high as today’s 5.2%.
At 1,530p, GSK’s shares are down 6.5% from 1,636p last quarter when its P/E was 14.5 and yield 4.9%. The forward 12-month earnings and dividend forecasts are little changed, so it’s the lower share price alone that accounts for the more attractive valuation today.
Elsewhere, shares of National Grid, which I spotlighted for you last quarter, have since edged down 1.8%. This has been enough to take the yield up to nudge 5% for the first time since my July 2015 review.
According to one leading industry firm, the 5G boom could create a global industry worth US $12.3 TRILLION out of thin air…
And if you click here, we’ll show you something that could be key to unlocking 5G’s full potential...
It’s just ONE innovation from a little-known US company that has quietly spent years preparing for this exact moment…
But you need to get in before the crowd catches onto this ‘sleeping giant’.
G A Chester has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended HSBC Holdings, Royal Dutch Shell B, and Sage Group. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.